Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Iowa: - Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- McFarland Clinic - Boone — Boone, Iowa
- Saint Anthony Regional Hospital — Carroll, Iowa
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Iowa: - UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- Saint Anthony Regional Hospital — Carroll, Iowa
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic — Clive, Iowa
- Blank Children's Hospital — Des Moines, Iowa
- Iowa Methodist Medical Center — Des Moines, Iowa
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in Iowa: - Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- Saint Anthony Regional Hospital — Carroll, Iowa
- Mercy Hospital — Cedar Rapids, Iowa
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Sites in Iowa: - UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic — Clive, Iowa
- Iowa Methodist Medical Center — Des Moines, Iowa
- UI Health Care Mission Cancer and Blood - Des Moines Clinic — Des Moines, Iowa
- Broadlawns Medical Center — Des Moines, Iowa
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Iowa: - University of Iowa Health Care. ( Site 0017) — Iowa City, Iowa
- University of Iowa Health Care. ( Site 0057) — Waukee, Iowa
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). …
Sponsor: BeOne Medicines
NCT ID: NCT06943872
Sites in Iowa: - University of Iowa Hospitals and Clinics — Iowa City, Iowa
- Mission Cancer and Blood — Waukee, Iowa
Phase 3 Recruiting Industry
A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell ly…
Sponsor: Corvus Pharmaceuticals, Inc.
NCT ID: NCT06561048
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Iowa: - Blank Children's Hospital — Des Moines, Iowa
- University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa
Phase 2 Recruiting NIH
This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearran…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06649812
Sites in Iowa: - Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- McFarland Clinic - Boone — Boone, Iowa
- Mercy Hospital — Cedar Rapids, Iowa
- Oncology Associates at Mercy Medical Center — Cedar Rapids, Iowa
Phase 2 Recruiting Network
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleuce…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05633615
Sites in Iowa: - University of Iowa/Holden Comprehensive Cancer Center — Iowa City, Iowa
Phase 2 Recruiting Industry
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06890884
Sites in Iowa: - University of Iowa-Holden Comprehensive Cancer Center ( Site 0139) — Iowa City, Iowa
- Mission Blood & Cancer Care ( Site 0114) — Waukee, Iowa
Phase 1, Phase 2 Recruiting Industry
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Sponsor: BeOne Medicines
NCT ID: NCT05006716
Sites in Iowa: - University of Iowa Hospitals and Clinics — Iowa City, Iowa
Phase 2 Recruiting Industry
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have receive…
Sponsor: AstraZeneca
NCT ID: NCT06526793
Sites in Iowa: - Research Site — Iowa City, Iowa
- Research Site — Waukee, Iowa
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04609046
Sites in Iowa: - UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- Saint Anthony Regional Hospital — Carroll, Iowa
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic — Clive, Iowa
- Iowa Methodist Medical Center — Des Moines, Iowa
- UI Health Care Mission Cancer and Blood - Des Moines Clinic — Des Moines, Iowa
Recruiting Network
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer …
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06002828
Sites in Iowa: - Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- Mission Cancer and Blood - Ankeny — Ankeny, Iowa
- McFarland Clinic - Boone — Boone, Iowa
- Saint Anthony Regional Hospital — Carroll, Iowa
NA Recruiting Network
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in Iowa: - Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- Mission Cancer and Blood - Ankeny — Ankeny, Iowa
- McFarland Clinic - Boone — Boone, Iowa
- Saint Anthony Regional Hospital — Carroll, Iowa
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Iowa: - Massive Bio SYNERGY-AI site — Iowa City, Iowa
Recruiting Industry
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and th…
Sponsor: Tempus AI
NCT ID: NCT07154823
Sites in Iowa: - University of Iowa Hospital and Clinics — Iowa City, Iowa
Recruiting Academic/Other
The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this …
Sponsor: Stanford University
NCT ID: NCT02848274
Sites in Iowa: - University of Iowa — Iowa City, Iowa